Starpharma Holdings Valuation

Is PQ6A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PQ6A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PQ6A's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PQ6A's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PQ6A?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for PQ6A. This is calculated by dividing PQ6A's market cap by their current preferred multiple.
What is PQ6A's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	AU$49.44m

PQ6A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.9x
Enterprise Value/EBITDA	-2.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PQ6A's PS Ratio compare to its peers?

The above table shows the PS ratio for PQ6A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.3x
SBX SynBiotic	5.1x	33.8%	€41.6m
B8F Biofrontera	0.8x	n/a	€21.8m
0RX Redx Pharma	13.3x	-37.6%	€65.0m
APPH Apontis Pharma	2x	17.7%	€73.0m
PQ6A Starpharma Holdings	4.7x	n/a	€49.4m

Price-To-Sales vs Peers: PQ6A is good value based on its Price-To-Sales Ratio (4.7x) compared to the peer average (5.3x).

Price to Earnings Ratio vs Industry

How does PQ6A's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	20.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	20.8%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: PQ6A is expensive based on its Price-To-Sales Ratio (4.7x) compared to the European Pharmaceuticals industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is PQ6A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PQ6A PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PQ6A's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.